ArticleCancer immunology research2015
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.
Article in Cancer immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities.Cancer metastasis reviews · 2024Review
- Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Pigment cell & melanoma research · 2024Review
- Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.Nature medicine · 2023Article
- Leptomeningeal Metastases: New Opportunities in the Modern Era.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Article
- Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.Current oncology reports · 2022Review
- Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.Cancers · 2021Review
- Leptomeningeal Carcinomatosis: Molecular Landscape, Current Management, and Emerging Therapies.Neurosurgery clinics of North America · 2020Review
- Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.Immunotherapy · 2020Article
- Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.Pigment cell & melanoma research · 2020Review
- T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.Journal of neuro-oncology · 2020Review
- A rare case of malignant meningitis from a likely bronchogenic melanoma primary cancer.Oxford medical case reports · 2019Article
- Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.American journal of clinical dermatology · 2018Review
- Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.ESMO open · 2018Article
- Review
- Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Pigment cell & melanoma research · 2016Review
- Cellular immunotherapy for malignant gliomas.Expert opinion on biological therapy · 2016Review
- Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.International journal of cancer · 2016Review
- Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledPatients with leptomeningeal disease (LMD) from melanoma have very poor outcomes and few treatment options. We present a case of intrathecal (i.t.) administration of autologous tumor-infiltrating lymphocytes (TIL) in a patient with LMD from metastatic melanoma. The patient developed LMD after previous treatments with surgery, high-dose bolus interleukin-2 (HD IL2), and systemic TIL infusion and experienced radiographic progression after intrathecal IL2 (i.t. IL2) therapy. The patient received weekly treatment with increasing numbers of i.t. TIL followed by twice-weekly i.t. IL2. The patient received three i.t. TIL infusions and did not experience any toxicities beyond those expected with i.t. IL2 therapy. Analysis of cerebrospinal fluid demonstrated increased inflammatory cytokines following the i.t. TREATMENTS: Subsequent imaging demonstrated disease stabilization, and neurological deficits also remained stable. The patient expired 5 months after the initiation of i.t. TIL therapy with disease progression in the brain, liver, lung, and peritoneal and retroperitoneal lymph nodes, but without LMD progression. These results demonstrate the safety of i.t. administration of TIL in melanoma patients with LMD and support the feasibility of conducting a prospective clinical trial to determine this therapy's clinical benefit among these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.